Related Experiment Video
Updated: Jun 21, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't
Alfredo Tartarone1, Michele Aieta
1Division of Medical Oncology, Centro di riferimento oncologico di Basilicata, I.R.C.C.S., via Padre Pio 1, Rionero in Vulture (PZ), Italy. tarta1@virgilio.it
Abstract:
Performance status (PS)2 patients with advanced non-small-cell lung cancer have been historically excluded from clinical trials, and scant data are available to guide clinical practice. As in other types of cancer, PS represents a recognized prognostic factor, and the life expectancy for PS2 patients is nearly half that of the PS0/1 patients. Even if single-agent chemotherapy still remains the reference treatment, recent data suggest a role for new agents or combination chemotherapy in these patients. A large Phase III randomized trial comparing single-agent versus combination chemotherapy is strongly needed.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers